Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
The ESC is involved in a number of EU funded research projects, often as a dissemination partner. Our role is fundamental to ensuring the very latest scientific best practice is shared with as many cardiovascular practitioners, researchers and institutions as possible.
ESC is a partner in this project that aims to improve care of patients with Atrial Fibrillation. Our role is to disseminate scientific findings through guideline recommendations and education programmes.
Beta 3 is a Horizon2020 funded project with an objective to prevent patients having a structural heart remodelling and therefore at risk, to develop a heart failure. Twelve partners in eight European countries participate to the Beta3_LVH project.
The project is a clinical trial with an already marketed drug, known to be effective in bladder disorders that will be administered to patients in a new indication.
The patients suffering from a structural and functional defect of the left ventricle are targeted. Their cardiac hypertrophy and left ventricle function will be monitored through the whole study to assess the possible benefit of the tested medication.
The targeted population is constituted of patients carrying structural cardiac disease with or without symptoms of heart failure (up to NYHA II), i.e. at risk of developing heart failure with preserved ejection fraction (HFpEF).
BETA 3_LVH website
Aims to outline the current Cardiovascular Diseases (CVD) research and innovation landscape across Europe
Learn more about Cardioscape
ESC will not participate in projects for endorsement purposes only.
Only projects related to the ESC mission statement and ESC strategic orientations will be considered. This includes of course Working groups, Councils and Associations.
The final decision will be taken by ESC leadership.